How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

163 results for

Cyclic Lipopeptide

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

161. In vitro activity of a new cyclic lipopeptide antibiotic, LY146032, against gram-positive clinical bacteria. (PubMed)

In vitro activity of a new cyclic lipopeptide antibiotic, LY146032, against gram-positive clinical bacteria. The in vitro activity of LY146032, a novel cyclic lipopeptide antibiotic, was tested against different gram-positive clinical isolates. The activity of LY146032 was clearly higher than that of vancomycin against all isolates tested. However, in some instances rifampin and imipenem showed higher activity than did LY146032.

Full Text available with Trip Pro

1987 Antimicrobial Agents and Chemotherapy

162. In vitro and in vivo activity of LY 146032, a new cyclic lipopeptide antibiotic. (PubMed)

In vitro and in vivo activity of LY 146032, a new cyclic lipopeptide antibiotic. The in vitro activity of LY 146032, a cyclic lipopeptide antibiotic belonging to the class of agents designated A21978C, was compared with those of vancomycin, cefpirome, cefotaxime, and clindamycin against selected gram-positive bacteria. The new drug inhibited all staphylococcal isolates, including methicillin-resistant strains, at concentrations of less than or equal to 1.0 microgram/ml. The activity of LY

Full Text available with Trip Pro

1986 Antimicrobial Agents and Chemotherapy

163. In vitro selection of bacteria resistant to LY146032, a new cyclic lipopeptide. (PubMed)

In vitro selection of bacteria resistant to LY146032, a new cyclic lipopeptide. Isolates of Streptococcus pneumoniae, Enterococcus faecalis, Enterococcus faecium, and coagulase-positive and -negative staphylococci were investigated for their abilities, in vitro, to develop resistance to LY146032. Exposure of the organisms to incremental concentrations of LY146032 resulted in MICs 8- to 32-fold higher than those for the original isolates. After three passages on antibiotic-free medium, the high

Full Text available with Trip Pro

1988 Antimicrobial Agents and Chemotherapy

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>